EUR 0.44
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 19.39 Million EUR | 24.66% |
2022 | 15.56 Million EUR | 12.16% |
2021 | 13.87 Million EUR | -35.71% |
2020 | 21.58 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 17.37 Million EUR | 0.0% |
2024 Q1 | 17.37 Million EUR | -10.43% |
2023 FY | 19.39 Million EUR | 24.66% |
2023 Q3 | 19.39 Million EUR | -11.43% |
2023 Q1 | 21.9 Million EUR | 40.75% |
2023 Q4 | 19.39 Million EUR | 0.0% |
2023 Q2 | 21.9 Million EUR | 0.0% |
2022 Q4 | 15.56 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Nicox S.A. | 31.56 Million EUR | 38.55% |
European Medical Solutions | 33.86 Million EUR | 42.721% |
argenx SE | 402.79 Million EUR | 95.184% |
BioSenic S.A. | 32.26 Million EUR | 39.877% |
Celyad Oncology SA | 9.97 Million EUR | -94.408% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -125.244% |
Onward Medical N.V. | 25.69 Million EUR | 24.516% |
Oxurion NV | 19.73 Million EUR | 1.713% |
PHAXIAM Therapeutics S.A. | 25.69 Million EUR | 24.507% |
Financière de Tubize SA | 123.65 Million EUR | 84.312% |
UCB SA | 6.56 Billion EUR | 99.704% |